Compare · NOTV vs SLGC
NOTV vs SLGC
Side-by-side comparison of Inotiv Inc. (NOTV) and SomaLogic Inc. (SLGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NOTV and SLGC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- SLGC is the larger of the two at $1.43B, about 514.1x NOTV ($2.8M).
- NOTV has hit the wire 8 times in the past 4 weeks while SLGC has been quiet.
- NOTV has more recent analyst coverage (9 ratings vs 6 for SLGC).
- Company
- Inotiv Inc.
- SomaLogic Inc.
- Price
- $0.08-14.45%
- $2.09-5.43%
- Market cap
- $2.8M
- $1.43B
- 1M return
- -72.65%
- -
- 1Y return
- -95.43%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 8
- 0
- Recent ratings
- 9
- 6
Inotiv Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Latest NOTV
- Inotiv Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Inotiv Announces Confirmation of Plan of Reorganization
- Chief Financial Officer Taylor Beth A. covered exercise/tax liability with 5,864 shares, decreasing direct ownership by 4% to 139,616 units (SEC Form 4) (for tax liability)
- Chief Strategy Officer Sagartz John E covered exercise/tax liability with 6,071 shares, decreasing direct ownership by 0.83% to 729,626 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Hardy Adrian covered exercise/tax liability with 5,371 shares, decreasing direct ownership by 9% to 53,049 units (SEC Form 4) to satisfy withholding tax
- VP-Finance & Corp. Controller Freeman Jeffrey Brennan covered exercise/tax liability with 5,855 shares, decreasing direct ownership by 14% to 36,623 units (SEC Form 4) (tax withholding)
- EVP, GC, Sec'y & CCO Castetter Andrea covered exercise/tax liability with 5,800 shares, decreasing direct ownership by 11% to 49,200 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Beattie John Gregory covered exercise/tax liability with 5,769 shares, decreasing direct ownership by 3% to 180,992 units (SEC Form 4) (withholding obligation)
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest SLGC
- OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)
- SEC Form 15-12G filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- SEC Form EFFECT filed by SomaLogic Inc.
- Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Ryan Jason
- Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Post Richard A returned 57,430 shares to the company, closing all direct ownership in the company (SEC Form 4)